
    
      This trial is a phase 3 study to evaluate efficacy and safety of co-administrated
      Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine in patients with primary
      hypercholesterolemia and essential hypertension.

      In "Rosuvastatin/Ezetimibe+Telmisartan/Amlodipine" treatment group, 48 subjects will be
      assigned and the subjects administer "Rosuvastatin/Ezetimibe+Telmisartan/Amlodipine" for 8
      weeks.

      In "Rosuvastatin/Ezetimibe +Telmisartan " treatment group, 48 subjects will be assigned and
      the subjects administer "Rosuvastatin/Ezetimibe+Telmisartan" for 8 weeks.

      In "Telmisartan/Amlodipine" treatment group, 48 subjects will be assigned and the subjects
      administer "Telmisartan/Amlodipine" for 8 weeks.
    
  